For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 17,957 | 3,357* | 2,536 | 2,533 |
| General and administrative expenses | 19,713 | 3,784* | 2,315 | 2,673 |
| Long-lived asset impairment | - | 0* | - | - |
| Acquired in-process research and development | 132,957 | - | - | - |
| Total operating expenses | 170,627 | 7,140 | 4,851 | 5,206 |
| Loss from operations | -170,627 | -7,140* | -4,851 | -5,206 |
| Interest income, net | 392 | 324* | 289 | 321 |
| Interest expense | - | 8* | 6 | 10 |
| Loss on asset disposal | - | - | -1 | -40 |
| Other (expense) income, net | -1 | -2* | 0 | -1 |
| Net loss | -170,236 | -6,827 | -4,569 | -4,936 |
| Net loss attributable to common stockholders | - | -6,827 | - | - |
| Basic EPS | -131.45 | -5.418 | -3.62 | -3.91 |
| Diluted EPS | -131.45 | -5.418 | -3.62 | -3.91 |
| Basic Average Shares | 1,295,052 | 1,260,159 | 1,261,290 | 1,260,867 |
| Diluted Average Shares | 1,295,052 | 1,260,159 | 1,261,290 | 1,260,867 |
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)